<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Conferences Archives - Myeloma Patients Europe</title>
	<atom:link href="https://www.mpeurope.org/category/conferences/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.mpeurope.org/category/conferences/</link>
	<description></description>
	<lastBuildDate>Thu, 01 Oct 2026 15:47:44 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://www.mpeurope.org/wp-content/uploads/2023/07/logo_MPE-fav-1-150x150.png</url>
	<title>Conferences Archives - Myeloma Patients Europe</title>
	<link>https://www.mpeurope.org/category/conferences/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>MPE strengthens patient voice in cancer quality-of-life research at EORTC meeting</title>
		<link>https://www.mpeurope.org/mpe-strengthens-patient-voice-in-cancer-quality-of-life-research-at-eortc-meeting/</link>
					<comments>https://www.mpeurope.org/mpe-strengthens-patient-voice-in-cancer-quality-of-life-research-at-eortc-meeting/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 12:12:29 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[Sin categoría]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=117213</guid>

					<description><![CDATA[<p>Last week MPE was in Zagreb for the Autumn EORTC Quality of Life Group meeting, connecting with colleagues working to strengthen the role of quality-of-life data in cancer research. The EORTC is the European Organisation for Research and Treatment of Cancer, a cancer research organisation that brings people together to answer important questions about which&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/mpe-strengthens-patient-voice-in-cancer-quality-of-life-research-at-eortc-meeting/">MPE strengthens patient voice in cancer quality-of-life research at EORTC meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="117213" class="elementor elementor-117213" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-7977c0e elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="7977c0e" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0ba2608" data-id="0ba2608" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-a5cb043 elementor-widget elementor-widget-text-editor" data-id="a5cb043" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p dir="ltr">Last week MPE was in Zagreb for the Autumn EORTC Quality of Life Group meeting, connecting with colleagues working to strengthen the role of quality-of-life data in cancer research.</p><p dir="ltr">The <a href="https://www.eortc.org/" target="_blank" rel="noopener">EORTC is the European Organisation for Research and Treatment of Cancer</a>, a cancer research organisation that brings people together to answer important questions about which cancer treatments work best and what their impact is on patients&#8217; lives. The Quality of Life group focuses on measuring and understanding patients&#8217; quality of life in cancer research.</p><p dir="ltr">Ahead of the official meeting, MPE&#8217;s Board Member Vincent Claus contributed to the pilot in-person SISAQOL training course. SISAQOL was a collaborative project that developed recommendations for designing, analysing, presenting and interpreting patient-reported data in cancer clinical trials. MPE was a work package lead on this European Union-funded project. Over the training course, participants learned and discussed how to apply the SISAQOL project recommendations.</p><p dir="ltr">MPE&#8217;s Head of Patient Research, Eilidh Duncan, attended the two-day in-person Quality of Life group meeting and represents MPE on a number of active projects within the group. These projects include the development of measures to capture patients&#8217; experiences of T-cell engaging immunotherapies and to understand the impact of cancer and treatments on finances.</p><p dir="ltr">The meeting and discussions provide an important opportunity to bring the perspectives of the patient community and patient advocates into the group&#8217;s work. It also enables MPE to learn from others and share this learning with our members and community on new developments and best practices in quality of life measurement, analysis and interpretation.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/mpe-strengthens-patient-voice-in-cancer-quality-of-life-research-at-eortc-meeting/">MPE strengthens patient voice in cancer quality-of-life research at EORTC meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/mpe-strengthens-patient-voice-in-cancer-quality-of-life-research-at-eortc-meeting/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Highlights from the International Myeloma Society (IMS) annual meeting</title>
		<link>https://www.mpeurope.org/highlights-from-the-international-myeloma-society-ims-annual-meeting/</link>
					<comments>https://www.mpeurope.org/highlights-from-the-international-myeloma-society-ims-annual-meeting/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Wed, 30 Sep 2026 14:06:51 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[CERVINO]]></category>
		<category><![CDATA[EXCALIBER-RRMM]]></category>
		<category><![CDATA[IMS highlights]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=117182</guid>

					<description><![CDATA[<p>From September 23-26, Myeloma Patients Europe (MPE) attended the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland. The IMS Annual Meeting is one of the most important international conferences for myeloma researchers and healthcare professionals, bringing together experts to discuss basic science, preclinical research and clinical developments in myeloma. More than 3,000 people&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/highlights-from-the-international-myeloma-society-ims-annual-meeting/">Highlights from the International Myeloma Society (IMS) annual meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="117182" class="elementor elementor-117182" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-8897e54 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="8897e54" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8bfd88f" data-id="8bfd88f" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-4586325 elementor-widget elementor-widget-text-editor" data-id="4586325" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">From September 23-26, Myeloma Patients Europe (MPE) attended the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland. The IMS Annual Meeting is one of the most important international conferences for myeloma researchers and healthcare professionals, bringing together experts to discuss basic science, preclinical research and clinical developments in myeloma. More than 3,000 people from over 75 countries attended this year’s meeting.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">MPE was there to learn about the latest developments in myeloma treatment, diagnosis and monitoring, and to make sure that patients’ perspectives and priorities are represented in discussions about the future of myeloma care. Here are some of the highlights we took away from this year&#8217;s meeting:</span><span data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-ba96bb1 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="ba96bb1" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cdd000f" data-id="cdd000f" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-8a4eba6 elementor-widget elementor-widget-heading" data-id="8a4eba6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Looking at the whole person </h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-1ec3f1c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="1ec3f1c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a194fc6" data-id="a194fc6" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0d958c6 elementor-widget elementor-widget-text-editor" data-id="0d958c6" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>The Nursing and allied health symposium had a strong focus on the importance of quality of life and understanding what matters to patients.</p><p>One key message was that a frailty score alone does not always give a complete picture of someone&#8217;s health. A full geriatric assessment can consider areas such as mobility, mood and ability to carry out everyday activities, helping healthcare teams identify areas where support could help. The symposium emphasized listening to patients, as healthcare professionals may underestimate symptom severity. Patient-reported outcome measures (PROMs) can help healthcare teams and researchers understand the impact of myeloma and its treatments more fully.</p><p>We also heard how, as treatments become increasingly effective, health-related quality of life and PROMs will become increasingly important in clinical trials. We want to see clinical trials place greater emphasis on what matters to patients, including symptoms, side effects and how treatments affect everyday life, particularly when treatments offer similar levels of disease control.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-cddba0f elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="cddba0f" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4b2a6d9" data-id="4b2a6d9" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-92bf623 elementor-widget elementor-widget-heading" data-id="92bf623" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Blood tests for diagnosing and monitoring myeloma  </h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-48dca87 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="48dca87" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3540fc8" data-id="3540fc8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-85d943a elementor-widget elementor-widget-text-editor" data-id="85d943a" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">There was a lot of interest in new blood-based technologies for diagnosing and monitoring myeloma. Many aspects of disease monitoring, including assessing treatment response and minimal residual disease (MRD), currently involve collecting a bone marrow sample through a biopsy. People living with myeloma can have negative experiences of bone marrow biopsies, so there is interest in whether blood-based approaches could make monitoring easier and improve quality of life.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">Several approaches are being studied, including looking for circulating tumour cells, using mass spectrometry to detect very small amounts of paraprotein, and analysing circulating tumour DNA. These techniques may help detect very small amounts of disease, assess risk and monitor treatment response. However, most blood-based approaches are not yet ready to replace bone marrow testing, which remains the gold standard test.</span><span data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-c352f9a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="c352f9a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ecb4db6" data-id="ecb4db6" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0154bca elementor-widget elementor-widget-heading" data-id="0154bca" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Preventing infections and side effects </h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-ff9ec45 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="ff9ec45" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a7db0e8" data-id="a7db0e8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-759e3b6 elementor-widget elementor-widget-text-editor" data-id="759e3b6" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">A key message from the meeting was that infection risk changes over time and is different for different treatments. Rather than using a one-size-fits-all approach, healthcare teams are increasingly looking at how immune function, blood counts and other risk factors can be used to tailor infection prevention to each person.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">There was also discussion about whether adjusting treatment schedules, including reducing how often some treatments are given or using fixed-duration treatment, could reduce the risk of infections and other side effects while maintaining treatment benefits.</span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-c9ee42d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="c9ee42d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8d4c14b" data-id="8d4c14b" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6eb8833 elementor-widget elementor-widget-heading" data-id="6eb8833" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Developments in myeloma treatment </h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-3619901 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="3619901" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2a2da28" data-id="2a2da28" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0defb71 elementor-widget elementor-widget-text-editor" data-id="0defb71" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Treatment developments were another important part of the meeting, with new results highlighting advances in both relapsed/refractory and newly diagnosed myeloma. Of note:</p><p>The <strong>CERVINO</strong> clinical trial showed that the investigational bispecific antibody etentamig improved response rates and helped people stay free from worsening myeloma for longer, compared with standard available treatments in people whose myeloma had already been exposed to three major classes of treatment. The treatment was given once every four weeks, which is more convenient for patients than the more frequent dosing schedules used for some other bispecific antibodies. Watch our interview explaining the outcomes of the CERVINO clinical trial.</p><p><span class="TextRun SCXW251682662 BCX8" lang="EN-GB" xml:lang="EN-GB" data-contrast="auto"><span class="NormalTextRun SCXW251682662 BCX8">The </span></span><strong><span class="TextRun SCXW251682662 BCX8" lang="EN-GB" xml:lang="EN-GB" data-contrast="auto"><span class="NormalTextRun SCXW251682662 BCX8">EXCALIBER-RRMM</span></span></strong><span class="TextRun SCXW251682662 BCX8" lang="EN-GB" xml:lang="EN-GB" data-contrast="auto"> <span class="NormalTextRun SCXW251682662 BCX8">clinical trial </span><span class="NormalTextRun SCXW251682662 BCX8">found that </span><span class="NormalTextRun SpellingErrorV2Themed SCXW251682662 BCX8">iberdomide</span><span class="NormalTextRun SCXW251682662 BCX8">, a newer type of immunomodulatory drug, combined with daratumumab and dexamethasone led to deeper responses than daratumumab, </span><span class="NormalTextRun SCXW251682662 BCX8">bortezomib</span><span class="NormalTextRun SCXW251682662 BCX8"> and dexamethasone in people with relapsed or refractory myeloma.</span><span class="NormalTextRun SCXW251682662 BCX8"> There were more problems with low levels of neutrophils </span><span class="NormalTextRun SCXW251682662 BCX8">(neutropenia) </span><span class="NormalTextRun SCXW251682662 BCX8">and infections with the </span><span class="NormalTextRun SpellingErrorV2Themed SCXW251682662 BCX8">iberdomide</span><span class="NormalTextRun SCXW251682662 BCX8"> combination, but nerve damage (peripheral neuropathy) was less common.</span> Watch our interview explaining the EXCALIBER-RRMM clinical trial.</span><span class="EOP Selected SCXW251682662 BCX8" data-ccp-props="{}"> </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-0ad4a39 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="0ad4a39" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-164ea96" data-id="164ea96" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-14001b3 elementor-widget elementor-widget-video" data-id="14001b3" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/rSbclS53uTg?si=aewmS6Od_0dR-I-k&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-0230dde" data-id="0230dde" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-3c84867 elementor-widget elementor-widget-video" data-id="3c84867" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/00A6iYKwRG0?si=-IzxMy-kCJIkjr5i&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-3e99d87 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="3e99d87" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-22e469e" data-id="22e469e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-ed69d5d elementor-widget elementor-widget-heading" data-id="ed69d5d" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">MPE at IMS</h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-142d863 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="142d863" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f6ac68e" data-id="f6ac68e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b9fada3 elementor-widget elementor-widget-text-editor" data-id="b9fada3" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">We were pleased to share MPE&#8217;s research at the meeting: </span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">We presented a poster on how myeloma clinical trials can better include people from groups that are often underrepresented in research.  It is important that clinical trials include the wide range of people affected by myeloma, so that new treatments work well for different people and communities and can be trusted by those who use them. Our research found that many approaches to making clinical research more inclusive were developed in the US. While these have often focused on improving inclusion across different ethnic groups, other factors that can affect someone’s opportunity to take part, such as mental health and their ability to give informed consent have received less attention. The approaches may therefore need to be adapted to ensure they are relevant to patients across Europe.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">We also took part in the </span><b><span data-contrast="auto">first ever patient group session at IMS</span></b><span data-contrast="auto">, where we had the opportunity to share MPE&#8217;s priorities and our work to improve access to treatment and care across Europe, alongside other international patient organisations. We are grateful to the IMS for creating opportunities for patient organisations to be part of these discussions. As MPE Co-CEO Kate Morgan said during the meeting:</span><span data-ccp-props="{}"> </span></p><p><em><strong>“We need to be working not just with other patient organisations but also with the IMS, industry and academic groups to tackle the shared challenges in myeloma and to bring the innovation we’ve seen this weekend to patients globally.” </strong></em></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-4ae35ac elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="4ae35ac" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f13bbf8" data-id="f13bbf8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-3ccdf45 elementor-widget elementor-widget-heading" data-id="3ccdf45" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Looking ahead</h4>				</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-ab55af0 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="ab55af0" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e83133c" data-id="e83133c" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b024b11 elementor-widget elementor-widget-text-editor" data-id="b024b11" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span data-contrast="auto">For MPE, the important question is </span><b><span data-contrast="auto">not only what new treatments can achieve, but also what the experience of receiving those treatments is like for patients</span></b><span data-contrast="auto">. Treatments need to be effective, but they also need to fit into people&#8217;s lives, support quality of life and be accessible to the people who need them.</span><span data-ccp-props="{}"> </span></p><p><span data-contrast="auto">If you have any questions or comments about IMS 2026, please contact </span><a href="mailto:info@mpeurope.org"><span data-contrast="none">info@mpeurope.org</span></a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/highlights-from-the-international-myeloma-society-ims-annual-meeting/">Highlights from the International Myeloma Society (IMS) annual meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/highlights-from-the-international-myeloma-society-ims-annual-meeting/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dr. Faith Davies interview on IMS 2026</title>
		<link>https://www.mpeurope.org/prof-faith-davies-interview-on-ims-2026/</link>
					<comments>https://www.mpeurope.org/prof-faith-davies-interview-on-ims-2026/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Thu, 17 Sep 2026 13:04:55 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=117047</guid>

					<description><![CDATA[<p>As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert Dr. Faith Davies, from NYU Langone, about her expectations for the meeting and why it is important for patient advocacy groups like MPE to attend. What are you looking forward to most about IMS 2026? I&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/prof-faith-davies-interview-on-ims-2026/">Dr. Faith Davies interview on IMS 2026</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="117047" class="elementor elementor-117047" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-8662c99 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="8662c99" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-8949df8" data-id="8949df8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-d8ee07e elementor-widget elementor-widget-spacer" data-id="d8ee07e" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-e22223c elementor-widget elementor-widget-text-editor" data-id="e22223c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert <strong>Dr. Faith Davies, from NYU Langone,</strong> about her expectations for the meeting and why it is important for patient advocacy groups like MPE to attend.</p><h4>What are you looking forward to most about IMS 2026?</h4><p>I am really looking forward to spending four days talking and thinking about myeloma! There has been so much happening in the field recently that concentrating on the new advances will be incredible. IMS gives me chance to think about how I can incorporate the new advances into my own practice, and what the knowledge gaps are for new research.</p><p>The myeloma community is quite small, so the meeting is also great opportunity to meet up with old friends and colleagues. It is often conversations over coffee (or a beer!) that have the greatest impact. For example, hearing how someone has successfully managed a difficult clinical case or learning about a new laboratory technique. </p>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-07dd58d" data-id="07dd58d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-3edaa18 elementor-widget__width-initial elementor-widget elementor-widget-image" data-id="3edaa18" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img fetchpriority="high" decoding="async" width="934" height="1024" src="https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-934x1024.png" class="attachment-large size-large wp-image-117079" alt="Faith Davies" srcset="https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-934x1024.png 934w, https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-274x300.png 274w, https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-768x842.png 768w, https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-1400x1536.png 1400w, https://www.mpeurope.org/wp-content/uploads/2026/09/Faith-Davies-1867x2048.png 1867w" sizes="(max-width: 934px) 100vw, 934px" />															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-dc0d91a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="dc0d91a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0d231f0" data-id="0d231f0" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-010a2d9 elementor-widget elementor-widget-text-editor" data-id="010a2d9" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<h4><strong>You are chairing the plenary abstract session. What is the key data we will see in this session?</strong></h4><p>It is a real honour to chair the plenary abstract session which showcases some of the most exciting abstracts at the meeting. These abstracts cover important topics such as long-term outcomes for newly diagnosed patients, novel treatments for relapsed patients and new insights on the biology of myeloma.</p><p>Some of the abstracts are reporting their data about the results of clinical trials including data on etentamig, a second-generation BCMA x CD3 bispecific antibody; iberdomide, a CELMOD and an in-vivo dual targeting CART. We also have two more laboratory-based abstracts. One looking at how a protein called NSD2 can be therapeutically targeted in patients with t(4;14) myeloma and another looking at how we can identify ultra high-risk patients who may not respond well to current therapies.</p><h4><strong>What other developments should MPE and our members be paying attention to?</strong></h4><p>A key theme throughout the meeting will be about safety and efficacy of bispecific and CAR T-cell therapies, including a session on infections. There will also be a lot of discussions on the best sequencing of treatments for patients and on side-effect management. For me, it is not yet clear what the best sequences of treatment are for patients, so I am looking forward to hearing people’s views and joining in the lively debates!</p><h4><strong>Why is it important for patient groups like MPE to be involved in IMS?</strong></h4><p>One of the main reasons so much progress has been made in myeloma is the ability of everyone to work together, including researchers, pharmaceutical companies, doctors and nurses, regulatory agencies, patient organisations and patients. It is so important that everyone has a seat at the table particularly as there are so many advances in therapy, many of which have big implications for treating physicians, healthcare utilisation and patient life expectancy. MPE will be able to present their research, learn about new developments and, importantly, share their perspectives on what patients think, need, and value as we move forward together. </p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-b3fce2f elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b3fce2f" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e8e167d" data-id="e8e167d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/prof-faith-davies-interview-on-ims-2026/">Dr. Faith Davies interview on IMS 2026</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/prof-faith-davies-interview-on-ims-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>IMS President Philippe Moreau previews this months IMS Annual Meeting</title>
		<link>https://www.mpeurope.org/preview-to-ims-annual-meeting-2026/</link>
					<comments>https://www.mpeurope.org/preview-to-ims-annual-meeting-2026/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 08:36:10 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[Myeloma]]></category>
		<category><![CDATA[IMS]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116831</guid>

					<description><![CDATA[<p>Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000 delegates from around the world, features presentations on the most important data and topics in myeloma. MPE recently interviewed IMS President and member of the&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/preview-to-ims-annual-meeting-2026/">IMS President Philippe Moreau previews this months IMS Annual Meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116831" class="elementor elementor-116831" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-96009df elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="96009df" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-125767f" data-id="125767f" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-45c388a elementor-widget elementor-widget-text-editor" data-id="45c388a" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000 delegates from around the world, features presentations on the most important data and topics in myeloma.</p><p>MPE recently interviewed IMS President and member of the MPE Medical Advisory Committee, Prof. Dr. Philippe Moreau, to understand his perspective on the importance of the meeting and patient advocacy involvement.</p>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-65f3b5e" data-id="65f3b5e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-ed3e758 elementor-widget-tablet__width-initial elementor-widget elementor-widget-image" data-id="ed3e758" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://www.mpeurope.org/wp-content/uploads/elementor/thumbs/photo-PM-scaled-rsszmtcz9uovjm5voovz86vkqv8k3zg3h4cf56jc8o.jpg" title="Professor Phillipe Moreau" alt="Professor Phillipe Moreau" loading="lazy" />															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-6c3799b elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="6c3799b" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ec144fc" data-id="ec144fc" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-7be930d elementor-widget elementor-widget-text-editor" data-id="7be930d" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>What do you most look forward to about attending IMS?</strong></p><p>There is an extraordinary amount happening in myeloma today. New treatment approaches are producing deeper and more durable responses, and we are now having serious scientific conversations about cure that would have been difficult to imagine not long ago. Bringing more than 3,000 people together from around the world with a shared purpose of learning from one another and advancing the field is what makes the IMS Annual Meeting such an important gathering.</p><p><strong>In your opinion, what are the key topics and data that will be presented at this year’s meeting?</strong></p><p>The scientific programme reflects just how quickly myeloma research is advancing. We will see first findings from phase II and III studies, longer-term data from major clinical trials, and continued progress in immune-based therapies and treatment strategies. The plenary programme is especially exciting – it includes research that could inform frontline treatment, maintenance, relapsed and refractory disease and long-term outcomes. We will also continue the discussion around cure: how we define it, measure it and make it achievable for more patients.</p><p>Investigators increasingly view the IMS Annual Meeting as a key venue for presenting important new data. The meeting brings together experimental scientists, translational investigators and clinical physicians to discuss how important laboratory findings transition into next-generation clinical trials. The cutting-edge research presented represents the future of myeloma care. Ideas for clinical trials and new advancements in medicine are developed inside our meeting halls.</p><p>Our joint sessions with stakeholders including European Hematology Association (EHA) and patient organisations – including MPE, International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), Myeloma UK and Myeloma Australia &#8211; also allow us to examine progress from different perspectives.</p><p><strong>Why do you think having patient organisations on the agenda at IMS is important?</strong></p><p>Patients are at the heart of everything IMS does. Scientific progress is most meaningful when it remains connected to the priorities, experiences and needs of the people we are trying to serve. As a global organisation, IMS brings together clinicians, researchers, regulatory experts, patient advocates and other stakeholders from around the world. Having patient organisations on the agenda ensures we hear firsthand about the priorities and challenges facing patients across different countries and health systems.</p><p>It also allows patient advocates to learn from one another and build stronger relationships across borders, helping ensure advances in research. Clinical care and policy remain connected to what matters most to patients.</p><p><strong>What are the next steps for IMS working with patient organisations?</strong></p><p>Patient organisations have long been partners to IMS, particularly in advocacy and consensus-building. As the field advances, we want to deepen those relationships and incorporate patient perspectives early when developing recommendations, considering policy priorities and defining outcomes that matter in patient care, including quality of life.</p><p>The next step is not simply to bring more patient organisations into the conversation, but to create more opportunities for meaningful collaboration. We want to strengthen connections among patient organisations, clinicians and researchers and ensure that progress in myeloma translates into progress patients can see and experience.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-0e68c2c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="0e68c2c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-eea8684" data-id="eea8684" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-80a73dd elementor-widget elementor-widget-text-editor" data-id="80a73dd" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>The 23rd Annual Meeting of the <span class="" data-sfc-cp="" data-sfc-root="ep" data-copy-service-computed-style="font-family: &quot;Google Sans&quot;, Arial, sans-serif; font-size: 16px; font-weight: 400; margin: 0px; text-decoration: none; border-bottom: 0px rgb(10, 10, 10);"><a class="H23r4e" href="https://www.myelomasociety.org/events/23rd-ims-annual-meeting/" target="_blank" rel="noopener" data-ved="2ahUKEwiRu-3Gwc-WAxUBVkEAHWbjC80Qy_kOegoIAggACAEICRAB" data-hveid="CAIIAAgBCAkQAQ" data-copy-service-computed-style="font-family: &quot;Google Sans&quot;, Arial, sans-serif; font-size: 16px; font-weight: 500; margin: 0px; text-decoration: underline 1px rgb(26, 13, 171); border-bottom: 0px rgb(26, 13, 171);">International Myeloma Society</a><!--TgQPHd|||[[&quot;https://www.myelomasociety.org/events/23rd-ims-annual-meeting/&quot;,null,null,[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,[{&quot;1218&quot;:[16]}]],16,null,&quot;23rd Annual Meeting \u0026 Exposition - International Myeloma Society&quot;,&quot;The 23rd Annual Meeting of the International Myeloma Society (IMS) will take place from September 23–26, 2026 at the Scottish Events Campus in Glasgow, Scotland. The meeting focuses on the basic, preclinical, and clinical aspects of myeloma. The program includes: * Talks and symposia led by key opinion leaders * Keynote addresses * Joint sessions with regulatory agencies and other organizations * Meet the Expert sessions * Oral Abstracts * Poster presentations and discussion sessions The International Myeloma Society develops the program solely.&quot;,&quot;https://encrypted-tbn2.gstatic.com/images?q\u003dtbn:ANd9GcSwUF6xq7NngZU6RDNQr4dOXFJj1UDMfgsKNYznmfyKE1_3jWLzIfuQ8XlcBscEVxa2hExrvPome4kn_Ls&quot;,&quot;International Myeloma Society&quot;,&quot;https://encrypted-tbn3.gstatic.com/faviconV2?url\u003dhttps://www.myelomasociety.org\u0026client\u003dAIM\u0026size\u003d128\u0026type\u003dFAVICON\u0026fallback_opts\u003dTYPE,SIZE,URL&quot;,[[1788338899738001,4281857,3440108390],null,null,null,null,[[2,0,1,7]]],null,&quot;807ed1c0-497f-4b1a-b393-13f82daab5ed&quot;]]--></span> (IMS) takes place from 23-26 September, in Glasgow, Scotland.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/preview-to-ims-annual-meeting-2026/">IMS President Philippe Moreau previews this months IMS Annual Meeting</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/preview-to-ims-annual-meeting-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>EHA 2026 interviews and highlights</title>
		<link>https://www.mpeurope.org/eha-2026-interviews-and-highlights/</link>
					<comments>https://www.mpeurope.org/eha-2026-interviews-and-highlights/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Wed, 17 Jun 2026 12:01:31 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116187</guid>

					<description><![CDATA[<p>MPE at EHA 2026: Stockholm in review EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For the MPE team, it was a week of in-depth learning and valuable exchanges with stakeholders. What we did Across the congress we attended myeloma scientific&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/eha-2026-interviews-and-highlights/">EHA 2026 interviews and highlights</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116187" class="elementor elementor-116187" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-28a1795 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="28a1795" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e6340a0" data-id="e6340a0" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-034d2f5 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="034d2f5" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-82b4753" data-id="82b4753" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e286be1 elementor-widget elementor-widget-heading" data-id="e286be1" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default"><h1 style="margin:0cm !msorm;line-height:normal !msorm;line-height:107%">MPE at EHA 2026: Stockholm in review<span style="font-size: 35px"></span></h1></h2>				</div>
				</div>
				<div class="elementor-element elementor-element-162a2c3 elementor-widget elementor-widget-text-editor" data-id="162a2c3" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For the MPE team, it was a week of in-depth learning and valuable exchanges with stakeholders.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-08929d9 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="08929d9" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e798a7a" data-id="e798a7a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-159f06a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="159f06a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-84a74aa" data-id="84a74aa" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-f37f362 elementor-widget elementor-widget-heading" data-id="f37f362" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">What we did</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-3548f60 elementor-widget elementor-widget-text-editor" data-id="3548f60" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Across the congress we attended myeloma scientific sessions, EHA committee meetings, patient advocacy symposia, advisory boards and meetings with haematologists, researchers and industry. We had strong representation throughout the congress, including:</p><ul><li>MPE board members Snezana Doder and Barbara Leonardi presented patient perspectives on treatment access and inequality.<br /><a href="https://www.medscape.com/viewarticle/multiple-myeloma-patients-have-unequal-access-treatment-2026a1000kio?form=fpf" target="_blank" rel="noopener">Find out more here</a></li><li>Access and Policy Manager, Monica Racovita, took part in a ECLLA Multi-Stakeholder Panel Discussion: &#8220;Time Off Treatment in CLL: Clinical Control and Patient Priorities in Fixed-Duration Treatment.&#8221;</li><li>Head of Patient Research, Eilidh Duncan, presented MPE’s data on individualised treatment and shared decision-making alongside leading doctors, as well as a poster showing MPE’s research on real-world experiences of family carers supporting people with myeloma. <br /><a href="https://www.mpeurope.org/wp-content/uploads/2026/06/MPE-carer-poster-at-EHA-2026.pdf" target="_blank" rel="noopener">See poster here</a></li><li>Head of Medical Education and Scientific Engagement, Solène Clavreul, presented the results of MPE and TriNetX’s collaborative research on real-world eligibility and treatment decision factors, alternative treatments and outcomes of myeloma patients considered for CAR T-cell therapy in Germany</li><li>We brought 10 participants from our Advocate Development Programme to the congress as part of their ongoing training</li></ul>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-2064344 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="2064344" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2383ca7" data-id="2383ca7" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-944cfd1 elementor-widget elementor-widget-heading" data-id="944cfd1" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">What we heard: interviews and research highlights</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-b7466ac elementor-widget elementor-widget-text-editor" data-id="b7466ac" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>We filmed exclusive interviews with leading clinicians throughout the congress, interviewing some of the leading doctors from across Europe on the latest results on the most important myeloma and AL amyloidosis clinical trials.</p><p>Watch the videos below.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-5d1019f elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="5d1019f" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-674f648" data-id="674f648" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-84ec91d elementor-widget-tablet__width-initial elementor-widget elementor-widget-video" data-id="84ec91d" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=cPjVICdfMU0&amp;list=PLv4rnl_0w_0ZOh26ME0_46dXFs1qhh_dx&amp;index=4&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-412a3ae" data-id="412a3ae" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-47a9f96 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor" data-id="47a9f96" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Albert Oriol, explains the results of the MONUMENTAL-3 trial for relapsed/refractory myeloma patients, at EHA 2026.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-e468635 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="e468635" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-e10e703" data-id="e10e703" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2ca346c elementor-widget elementor-widget-video" data-id="2ca346c" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/T1ly0TJdg8g?si=JKZ19XSQlEtiGdXi&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-5115d1a" data-id="5115d1a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-26e39f2 elementor-widget elementor-widget-text-editor" data-id="26e39f2" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Cyrille Touzeau talks through the results from the phase III MajesTEC-9 clinical trial and explains the benefits of teclistamab monotherapy compared with standard of care combinations in patients with relapsed or refractory myeloma.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-29c4f44 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="29c4f44" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-1046abc" data-id="1046abc" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-d2bb5c6 elementor-widget elementor-widget-video" data-id="d2bb5c6" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=o_EE5gM96Oo&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-593206c" data-id="593206c" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-c4cb0e8 elementor-widget elementor-widget-text-editor" data-id="c4cb0e8" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Alberto Orial explains the results of the late breaking abstract SUCCESSOR-2 evaluating mezigdomide, carfilzomib and dexamethasone (mezikd) vs carfilzomib and dexamethasone (kd) in relapsed/refractory myeloma.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-3254982 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="3254982" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-9cc66d7" data-id="9cc66d7" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-9579702 elementor-widget elementor-widget-video" data-id="9579702" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/Qun69ChlMiQ&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-7cc28af" data-id="7cc28af" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e019c1f elementor-widget elementor-widget-text-editor" data-id="e019c1f" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Ashutosh Wechalekar, explains the phase III CARES clinical trial and the results show a survival benefit of adding the amyloid depleter anselamimab (also known as CAEL-101) to standard treatments in patients with newly diagnosed stage IIIa and IIIb AL amyloidosis.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-f69f0fa elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="f69f0fa" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-2678645" data-id="2678645" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-957f34c elementor-widget-tablet__width-initial elementor-widget elementor-widget-video" data-id="957f34c" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=NTMTfENCq5Q&amp;list=PLv4rnl_0w_0ZOh26ME0_46dXFs1qhh_dx&amp;index=2&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-7862f1d" data-id="7862f1d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-02fc79c elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor" data-id="02fc79c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Binod Dhakal, explains the phase 1 clinical trial known as CaMMouflage. This trial shows the safety and preliminary efficacy of the allogeneic anti-BCMA CAR T-cell therapy CB-011 in patients with relapsed or refractory myeloma.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-c5cb386 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="c5cb386" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-7e1c2df" data-id="7e1c2df" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-7c6be08 elementor-widget elementor-widget-video" data-id="7c6be08" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=hTKqYoyGt0Q&amp;list=PLv4rnl_0w_0ZOh26ME0_46dXFs1qhh_dx&amp;index=6&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-e0c4283" data-id="e0c4283" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0c95c2b elementor-widget elementor-widget-text-editor" data-id="0c95c2b" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Cyrille Touzeau explains the results of the phase 2 ERASMM (EMN34) study, which evaluates safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-532654f elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="532654f" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-3de5a9a" data-id="3de5a9a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e9a442a elementor-widget elementor-widget-video" data-id="e9a442a" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=ZrepfThei1k&amp;list=PLv4rnl_0w_0ZOh26ME0_46dXFs1qhh_dx&amp;index=7&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-5bf885e" data-id="5bf885e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-aeb5c47 elementor-widget elementor-widget-text-editor" data-id="aeb5c47" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Ashutosh Wechalekar explains the early efficacy and safety results from the phase I/II LINKER AL2 clinical trial. This trial shows promising results for the BCMA bispecific antibody linvoseltamab in patients with relapsed or refractory AL amyloidosis.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-84cc339 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="84cc339" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-b44e9a3" data-id="b44e9a3" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-ea04fed elementor-widget elementor-widget-video" data-id="ea04fed" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/ROzHXxSViBM?si=fjE8dQREYMfMZlww&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-fe6f09c" data-id="fe6f09c" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2aea03c elementor-widget elementor-widget-text-editor" data-id="2aea03c" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Dr. Claudio Cerchione, <em>Istituto Romagnolo</em> per lo Studio dei Tumori &#8220;Dino Amadori&#8221; (Italy), gives an overview of the highlights from EHA 2026.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-946653e elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="946653e" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-bc31f73" data-id="bc31f73" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-a0ebcbb elementor-widget elementor-widget-heading" data-id="a0ebcbb" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Plus, don’t forget to join our EHA highlights webinar</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-3cca888 elementor-widget elementor-widget-text-editor" data-id="3cca888" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On <strong>Tuesday 30 June at 17:00 CET</strong>, Dr. Johan Lund will take time to reflect on and break down the key research from EHA 2026 in a patient-friendly way.</p><p><a href="https://www.mpeurope.org/eha-webinar-2026" target="_blank" rel="noopener">Register here</a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-fdab779 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="fdab779" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7190559" data-id="7190559" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-357fbf1 elementor-widget-tablet__width-initial elementor-widget elementor-widget-image" data-id="357fbf1" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.mpeurope.org/eha-webinar-2026">
							<img decoding="async" width="500" height="500" src="https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-500x500.jpg" class="attachment-thumbrelated size-thumbrelated wp-image-116000" alt="Post EHA 2026 Webinar" srcset="https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-500x500.jpg 500w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-300x300.jpg 300w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-1024x1024.jpg 1024w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-150x150.jpg 150w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-768x768.jpg 768w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2.jpg 1080w" sizes="(max-width: 500px) 100vw, 500px" />								</a>
															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/eha-2026-interviews-and-highlights/">EHA 2026 interviews and highlights</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/eha-2026-interviews-and-highlights/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Myeloma EHA 2026 preview</title>
		<link>https://www.mpeurope.org/myeloma-eha-2026-preview/</link>
					<comments>https://www.mpeurope.org/myeloma-eha-2026-preview/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Mon, 01 Jun 2026 14:27:54 +0000</pubDate>
				<category><![CDATA[AL amyloidosis]]></category>
		<category><![CDATA[Conferences]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116136</guid>

					<description><![CDATA[<p>The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/myeloma-eha-2026-preview/">Myeloma EHA 2026 preview</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116136" class="elementor elementor-116136" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-915f2d6 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="915f2d6" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1ab0f25" data-id="1ab0f25" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-25835e9 elementor-widget elementor-widget-text-editor" data-id="25835e9" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>The <a href="https://ehaweb.org/connect-network/eha2026-congress" target="_blank" rel="noopener"><strong>European Hematology Association (EHA) 2026 Annual Congress</strong></a>, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis.</p><p>Myeloma Patients Europe (MPE) will be attending EHA to keep the patient community informed about key developments in treatment and care. Throughout the event, we will share real-time updates via our social media channels (LinkedIn, Facebook, Instagram, X and YouTube), including expert video interviews and key highlights from the scientific sessions.</p><p>MPE will also participate in various parts of the congress programme, including the satellite symposia, the EHA-Patient Joint Symposium and poster sessions. Make sure you are following us to receive real-time updates during the events.</p><h4><strong>Key research in myeloma and AL amyloidosis at EHA 2026</strong></h4><p>The EHA 2026 scientific programme includes many abstracts on myeloma and AL amyloidosis, covering both established and new treatment approaches. While this article won’t summarise all relevant research, these are the presentations which we believe will be of greatest interest to patients and the wider myeloma and AL amyloidosis community:</p><p>Many presentations will present positive results of bispecific antibodies in myeloma, including: </p><ul><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/teclistamab/"><strong>Teclistamab</strong>:</a> results from the phase III MajesTEC-9 clinical trial show the benefits of teclistamab monotherapy compared with standard of care combinations in patients with relapsed or refractory myeloma. </li><li><strong><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/teclistamab/">Teclistamab</a> and <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/daratumumab/">daratumumab</a></strong>: analyses from the phase III MajesTEC-3 clinical trial demonstrate the efficacy of teclistamab plus daratumumab across high-risk subgroups of patients with relapsed or refractory myeloma. </li><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/talquetamab/"><strong>Talquetamab</strong></a>: results from the phase III MONUMENTAL-3 clinical trial show the benefits of talquetamab plus daratumumab with or without pomalidomide compared to a combination of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma. <br /><br /></li><li><strong>Infection prevention with BCMA bispecific antibodies</strong>: results from a retrospective, real-world study show that primary prophylaxis (treatment before any infection occurs) with immunoglobulin-replacement therapy improves survival  in patients with myeloma treated with BCMA bispecific antibodies.<strong> </strong></li></ul><p>There will be several presentations dedicated to CAR T-cell therapies for the treatment of myeloma, including: </p><ul><li><strong>CB-011</strong>: early results from the phase I CAMMOUFLAGE clinical trial show the safety and preliminary efficacy of the allogeneic anti-BCMA CAR T-cell therapy CB-011 in patients with relapsed or refractory myeloma. </li><li><strong>Arlocabtagene autoleucel:</strong> an updated phase I clinical trial results show promising safety and efficacy of the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in patients with relapsed or refractory myeloma who received 1 to 3 prior lines of treatment. </li><li><strong>BMS-986453</strong>: preclinical and early clinical development data showing the potential of the dual-targeting BCMA andGPRC5D CAR T-cell therapy BMS-986453 in patients with relapsed or refractory myeloma.</li></ul><p>The treatment of newly diagnosed myeloma patients will also be addressed in several presentations, including:</p><ul><li><strong><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/daratumumab/">Daratumumab</a> + VRd</strong>: final analysis from the phase III CEPHEUS clinical trial confirms previously reported efficacy and safety results demonstrating the benefits of adding daratumumab to the <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/bortezomib/">bortezomib</a>, lenalidomide, and dexamethasone treatment combination in transplant-ineligible patients with newly diagnosed myeloma.</li><li><strong>Iberdomide + DVd</strong>: phase I/II results from the IDEAL clinical trial show the safety and efficacy of an iberdomide-based quadruplet regimen with <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/daratumumab/">daratumumab</a>, <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/bortezomib/">bortezomib</a>, and dexamethasone in patients with newly diagnosed myeloma.</li></ul><p>Smouldering myeloma treatment will also be covered, with a few presentations, including:</p><ul><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/elranatamab/"><strong>Elranatamab</strong></a>: first results from the phase II EMN34/ERASMM clinical trial show the safety and efficacy of elranatamab as a promising early intervention strategy in patients with high-risk smouldering myeloma. </li></ul><p>Several presentations will focus on AL amyloidosis treatment, including:</p><ul><li><strong>Anselamimab</strong>: results from the phase III CARES clinical trial show a survival benefit of adding the amyloid depleter anselamimab (also known as CAEL-101) to standard treatments in patients with newly diagnosed stage IIIa and IIIb AL amyloidosis.</li><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/linvoseltamab/"><strong>Linvoseltamab</strong></a>: early efficacy and safety results from the phase I/II LINKER AL2 clinical trial show promising results for the BCMA bispecific antibody linvoseltamab in patients with relapsed or refractory AL amyloidosis.</li><li><strong>Etentamig</strong>: safety and efficacy results from the phase I clinical trial confirm previously reported promising results for the BCMA bispecific antibody etentamig in patients with relapsed or refractory AL amyloidosis.</li></ul><h4><strong>MPE at EHA 2026</strong></h4><p>MPE will attend EHA 2026 to gather the most important updates on myeloma and AL amyloidosis and other key advocacy topics such as access to treatment and quality of life for patients. In particular, MPE will participate in the following sessions:</p><ul><li><strong>MPE board member, Snežana Doder,</strong> will share patients’ perspectives on treatment access during the session “Inequalities in drug access in lymphoid malignancies (multiple myeloma)” co-chaired by<strong> MPE President, Barbara Leonardi</strong> on Sunday, 14 June. </li></ul><ul><li><strong>MPE Head of Patient Research, Eilidh Duncan,</strong> will speak about shared decision-making and patients’ perspectives on treatment administration routes during the satellite symposium  “Individualisation Requires Communication: Working With Our Patients With Newly-Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes”, which will take place on Saturday, 13 June. </li></ul><ul><li><strong>MPE Head of Medical Education and Scientific Engagement, Solène Clavreul,  </strong>along with  Scientific and Data Strategy Lead at TriNetX,<em>  </em>Zuzana  Dostálová, will present the results of MPE and  TriNetX’s collaborative research on real-world eligibility and treatment decision factors, alternative treatments and outcomes of myeloma patients considered for CAR T-cell therapy in Germany in the poster session on Friday, 12 June.  </li></ul><ul><li><strong>MPE Head of Patient Research, Eilidh Duncan</strong>, will present the results of MPE’s research on real-world experiences of family carers supporting people with myeloma in the poster session on Friday, 12 June.  </li></ul><p>With so much data being presented, EHA 2026 promises to be an exciting meeting for the myeloma and AL amyloidosis community. MPE looks forward to sharing insights and analysis throughout and in the weeks after the event, including our EHA highlights webinar.So, be sure to follow us on all our channels for full coverage and register for our upcoming webinar! </p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-a8be4eb elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="a8be4eb" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-655ae0d" data-id="655ae0d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
				<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-8ce479e" data-id="8ce479e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-f671722 elementor-align-center elementor-widget elementor-widget-button" data-id="f671722" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://www.mpeurope.org/eha-webinar-2026/">
						<span class="elementor-button-content-wrapper">
						<span class="elementor-button-icon">
				<i aria-hidden="true" class="fas fa-arrow-alt-circle-right"></i>			</span>
									<span class="elementor-button-text">Register now</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-e87dfc7" data-id="e87dfc7" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/myeloma-eha-2026-preview/">Myeloma EHA 2026 preview</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/myeloma-eha-2026-preview/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Join our EHA 2026 highlights webinar</title>
		<link>https://www.mpeurope.org/eha-webinar-2026/</link>
					<comments>https://www.mpeurope.org/eha-webinar-2026/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Fri, 08 May 2026 13:09:17 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=115963</guid>

					<description><![CDATA[<p>To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 30 June at 17:00 CET. At this webinar you can expect clear explanations of the key research updates and&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/eha-webinar-2026/">Join our EHA 2026 highlights webinar</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="115963" class="elementor elementor-115963" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-1004c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="1004c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2c144cae" data-id="2c144cae" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-58df241e elementor-widget elementor-widget-text-editor" data-id="58df241e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 30 June at 17:00 CET.</p><p>At this webinar you can expect clear explanations of the key research updates and what they could mean for patients. You&#8217;ll also hear expert insights and have the chance to ask any questions you may have using Zoom&#8217;s Q&amp;A Function.</p><p>Whether you&#8217;re a patient, carer, or advocate, this webinar will help you stay informed and increase your understanding about the latest advances in myeloma treatment and research.</p><p>The session will be led by Sweden&#8217;s Dr. Johan Lund.</p><p><a href="https://mpeurope-org.zoom.us/webinar/register/WN_Yiz5t0UCSSmSAW2UUebGIA#/registration"><img decoding="async" class="aligncenter" title="register now" src="https://www.mpeurope.org/wp-content/uploads/2020/11/register-now.png" alt="register now" width="240" height="146" /></a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-6cb0231 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="6cb0231" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-390fe6e" data-id="390fe6e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2f7ce9f elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="2f7ce9f" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<h4>Meet the speaker</h4><p>Dr. Johan Lund is a senior consultant and affiliated researcher at the Department of Medicine at Karolinska Institutet in Stockholm, Sweden. His publications focus on hematology, particularly multiple myeloma, stem cell transplantation, cellular therapies and immunotherapy. He is affiliated with both the Hematological and Solid Tumors research group and the Cell and Gene Therapy research group at Karolinska Institutet. He obtained a PhD from the Department of Medicine, Huddinge, Karolinska Institutet, in 2016.</p>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-b7ea99e" data-id="b7ea99e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-763e58c elementor-widget__width-initial elementor-widget elementor-widget-image" data-id="763e58c" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
												<figure class="wp-caption">
											<a href="https://mpeurope-org.zoom.us/webinar/register/WN_Yiz5t0UCSSmSAW2UUebGIA#/registration" target="_blank">
							<img loading="lazy" decoding="async" width="768" height="768" src="https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-768x768.jpg" class="attachment-medium_large size-medium_large wp-image-116000" alt="Post EHA 2026 Webinar" srcset="https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-768x768.jpg 768w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-300x300.jpg 300w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-1024x1024.jpg 1024w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-150x150.jpg 150w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2-500x500.jpg 500w, https://www.mpeurope.org/wp-content/uploads/2026/05/Post-EHA-2026-Webinar-2.jpg 1080w" sizes="(max-width: 768px) 100vw, 768px" />								</a>
											<figcaption class="widget-image-caption wp-caption-text"></figcaption>
										</figure>
									</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/eha-webinar-2026/">Join our EHA 2026 highlights webinar</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/eha-webinar-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>ASH 2025 summary video interviews</title>
		<link>https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/</link>
					<comments>https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 12:19:14 +0000</pubDate>
				<category><![CDATA[AL amyloidosis]]></category>
		<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=114063</guid>

					<description><![CDATA[<p>The largest haematology meeting in the world has just finished. The American Society of Hematology (ASH) Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the most relevant studies and abstracts in myeloma and AL amyloidosis.&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/">ASH 2025 summary video interviews</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="114063" class="elementor elementor-114063" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-fa533e5 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="fa533e5" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-988725e" data-id="988725e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-f5a7164 elementor-widget elementor-widget-text-editor" data-id="f5a7164" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>The largest haematology meeting in the world has just finished. The<a href="https://submit.hematology.org/" target="_blank" rel="noopener"> American Society of Hematology (ASH)</a> Annual Congress took place in Orlando, Florida, US, where the latest research in blood diseases was presented. Myeloma Patients Europe (MPE) interviewed key experts to learn more about the<strong> most relevant studies and abstracts in myeloma and AL amyloidosis.</strong></p><p>Watch these interviews to learn what the most important updates were in myeloma and AL amyloidosis and why these results matter for people living with these conditions. <strong>Click on the thumbnails to watch.</strong></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-98b2f96 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="98b2f96" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-8a2225d" data-id="8a2225d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0f8d195 elementor-widget elementor-widget-video" data-id="0f8d195" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/youtu.be\/bxusv_EeOWQ?si=25ezuqMw93bKfAmx&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-58000d5" data-id="58000d5" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-eb82837 elementor-widget elementor-widget-spacer" data-id="eb82837" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-979fa88 elementor-widget elementor-widget-text-editor" data-id="979fa88" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On behalf of Myeloma Patients Europe, Prof. Dr. Hermann Einsele, shares his key myeloma highlights of the ASH 2025 conference.</p><p>Prof. Dr. Einsele is hematologist, oncologist, Professor of Internal Medicine and Director of the Department of Internal Medicine II at the University Hospital Würzburg in Germany. He is a world leading expert in the field of myeloma and immunotherapy and in particular CAR T-cells and bispecific antibodies.</p><p>He emphasised that the myeloma treatment landscape has never evolved as rapidly as today and we thank him for his encouraging words and his professional and insightful presentation.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-b321b78 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b321b78" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-367a6d6" data-id="367a6d6" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-12a1488 elementor-widget elementor-widget-spacer" data-id="12a1488" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-d9d8819 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="d9d8819" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-6cbc928" data-id="6cbc928" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b12a1a1 elementor-widget elementor-widget-image" data-id="b12a1a1" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://youtu.be/LEFWII_tnsc?si=4mxREndz2mONJQWG" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="167" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-300x167.png" class="attachment-medium size-medium wp-image-114071" alt="Dr. Charlotte Pawlyn" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-300x167.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-1024x571.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-768x428.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-1536x856.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn.png 1833w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-17508c9" data-id="17508c9" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2e45fc9 elementor-widget elementor-widget-text-editor" data-id="2e45fc9" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Charlotte Pawlyn &#8211; Majestec-3</strong></p><p>Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of MajesTEC-3, one of the most important myeloma studies. This trial compared the combination of teclistamab and daratumumab (Tec-Dara) versus daratumumab with either pomalidomide or bortezomib and dexamethasone in patients who had received one to three previous lines of treatment. The Tec-Dara combination showed unprecedented benefits when used earlier in the myeloma pathway.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-dd8028d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="dd8028d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-1fad1fe" data-id="1fad1fe" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2d77bfd elementor-widget elementor-widget-image" data-id="2d77bfd" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://youtu.be/gNdz4GN-fM4?si=d2kFwx9gUviwigJA" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="167" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-300x167.png" class="attachment-medium size-medium wp-image-114074" alt="Dr. Phoebe Joy Ho" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-300x167.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-1024x572.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-768x429.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-1536x858.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho.png 1836w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-338e1c0" data-id="338e1c0" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-586a488 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="586a488" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Phoebe Joy Ho &#8211; inMMyCAR</strong></p><p>Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, explains the results of inMMyCAR. This first-in-human study of KLN1010, a novel &#8220;in vivo&#8221; CAR T-cell therapy targeting BCMA, showed very good responses in four treated patients with no serious instances of cytokine release syndrome (CRS) or neurotoxicity (ICANs).</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-0c0ba79 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="0c0ba79" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-fb1788d" data-id="fb1788d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e091f22 elementor-widget elementor-widget-image" data-id="e091f22" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=jDoP3xCL8IE&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=9" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-300x168.png" class="attachment-medium size-medium wp-image-114070" alt="Dr. Bruno Paiva" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-1024x573.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-768x430.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-1536x860.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva.png 1834w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c4823bb" data-id="c4823bb" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-46c21cc elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="46c21cc" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Bruno Paiva &#8211; GEM-CESAR</strong></p><p>Dr. Bruno Paiva, Clínica Universidad de Navarra, Madrid, Spain, explains the main results of the GEM-CESAR clinical trial presented at ASH 2025. This a study assessing early rescue treatment with daratumumab, pomalidomide and dexamethasone (DPd) in people with high-risk smoldering myeloma.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-e67720c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="e67720c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-75fb656" data-id="75fb656" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-bd66eb7 elementor-widget elementor-widget-image" data-id="bd66eb7" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=8H9oLFY8olU&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=6" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard-300x168.png" class="attachment-medium size-medium wp-image-114069" alt="Dr. Shambavi Richard" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard-1024x575.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard-768x431.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard-1536x862.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Shambavi-Richard.png 1832w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-e1018c5" data-id="e1018c5" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-105b0a9 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="105b0a9" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Shambavi Richard &#8211; DURGA-1</strong></p><p>Dr. Shambavi Richard, Icahn School of Medicine at Mount Sinai, New York, United States, explains the main results of the DURGA-1 trial evaluating AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy using FasTCAR technology for rapid manufacturing. Early data showed promise for this dual-target approach in relapsed/refractory multiple myeloma patients.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-a2960a2 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="a2960a2" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-704ad85" data-id="704ad85" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-308b03c elementor-widget elementor-widget-image" data-id="308b03c" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=_CRE84vkyFY&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=2" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu-300x168.png" class="attachment-medium size-medium wp-image-114072" alt="Dr. Xavier Leleu" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu-1024x573.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu-768x430.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu-1536x860.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Xavier-Leleu.png 1832w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-58d1a83" data-id="58d1a83" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-76f0723 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="76f0723" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Xavier Leleu &#8211;  LINKER-MM4</strong></p><p>Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and efficacy of linvoseltamab as a simplified monotherapy in first-line regimen in newly diagnosed myeloma patients.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-94e7cc3 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="94e7cc3" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-58bba6e" data-id="58bba6e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-8065509 elementor-widget elementor-widget-image" data-id="8065509" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=OO5xYevqWZo&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=3" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="167" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-300x167.png" class="attachment-medium size-medium wp-image-114071" alt="Dr. Charlotte Pawlyn" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-300x167.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-1024x571.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-768x428.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn-1536x856.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Charlotte-Pawlyn.png 1833w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-7111155" data-id="7111155" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-2cec57b elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="2cec57b" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Charlotte Pawlyn &#8211; UK MRA FiTNESS trial </strong></p><p>Dr. Charlotte Pawlyn, from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of the MRA FiTNESS trial, which aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to a myeloma patient&#8217;s level of fitness.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-024f1e7 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="024f1e7" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-006f752" data-id="006f752" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-1f89043 elementor-widget elementor-widget-image" data-id="1f89043" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=H6EtYJ9xJ7g&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=7" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="167" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-300x167.png" class="attachment-medium size-medium wp-image-114074" alt="Dr. Phoebe Joy Ho" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-300x167.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-1024x572.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-768x429.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho-1536x858.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Phoebe-Joy-Ho.png 1836w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-a5ef877" data-id="a5ef877" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-be6d2c0 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="be6d2c0" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Phoebe Joy Ho &#8211; CAMMA-3</strong></p><p>Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of Sydney, Australia, explains the first results from the phase Ib CAMMA-3 study, in which subcutaneous cevostamab shows manageable safety and meaningful clinical activity in relapsed/refractory myeloma (RRMM).</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-4cd01c0 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="4cd01c0" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-125a8c3" data-id="125a8c3" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6ae61a6 elementor-widget elementor-widget-image" data-id="6ae61a6" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=rdUSgLnwf3Q&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=1" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld-300x168.png" class="attachment-medium size-medium wp-image-114073" alt="Dr. Dominik Dytfeld" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld-1024x573.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld-768x430.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld-1536x859.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr-Dominik-Dytfeld.png 1834w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-9e1671c" data-id="9e1671c" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-35351f8 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="35351f8" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Dominik Dytfeld &#8211; COBRA trial</strong></p><p>Dr. Dominik Dytfeld, Poznan University of Medical Sciences, Poland, lead author of the COBRA trial, explains this study evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM).</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-942f2a3 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="942f2a3" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-58636ae" data-id="58636ae" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-f7b1b47 elementor-widget elementor-widget-image" data-id="f7b1b47" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.youtube.com/watch?v=ORkRg5-8cFM&#038;list=PLv4rnl_0w_0aG6FKbncN6rbfiPPsHeUmh&#038;index=8" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-300x168.png" class="attachment-medium size-medium wp-image-114070" alt="Dr. Bruno Paiva" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-1024x573.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-768x430.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva-1536x860.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Bruno-Paiva.png 1834w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c5e8dad" data-id="c5e8dad" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0e8dc27 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="0e8dc27" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Bruno Pavia &#8211; NoMoreMGUS</strong></p><p>Dr. Bruno Paiva, Clínica Universidad de Navarra, Madrid, Spain, explains the main results of the NoMore MGUS clinical trials, one of the largest MGUS (Monoclonal Gammopathy of Undetermined Significance) data collection trials in the world.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-13262a9 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="13262a9" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c8bcd6a" data-id="c8bcd6a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-38485fc elementor-widget elementor-widget-image" data-id="38485fc" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://youtu.be/vju50NAOQlM?si=Z8LqnYnunbdTx-UB" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1-300x168.png" class="attachment-medium size-medium wp-image-114124" alt="Dr Salomon Manier" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1-1024x574.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1-768x431.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1-1536x862.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Salomon-Manier-1.png 1829w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-bdb2449" data-id="bdb2449" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-234b894 elementor-widget__width-initial elementor-widget elementor-widget-text-editor" data-id="234b894" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Salomon Manier &#8211; IFM2021-01 trial<br /></strong></p><p>Dr.Salomon Manier, University of Lille, France, talks through this <span data-teams="true">teclistamab </span>trial. This study shows that an “all-antibody–based” doublet regimen of teclistamab and daratumumab is highly effective and well-tolerated in elderly newly diagnosed myeloma patients. </p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-dbe30c6 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="dbe30c6" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-ccfc3a6" data-id="ccfc3a6" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-fa8afdd elementor-widget elementor-widget-image" data-id="fa8afdd" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://youtu.be/WQzv1iA3-Io" target="_blank">
							<img loading="lazy" decoding="async" width="300" height="168" src="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani-300x168.png" class="attachment-medium size-medium wp-image-114121" alt="Dr. Paolo Milani" srcset="https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani-300x168.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani-1024x573.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani-768x430.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani-1536x860.png 1536w, https://www.mpeurope.org/wp-content/uploads/2025/12/Dr.-Paolo-Milani.png 1832w" sizes="(max-width: 300px) 100vw, 300px" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-631d16a" data-id="631d16a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6baca63 elementor-widget elementor-widget-text-editor" data-id="6baca63" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><strong>Dr. Paolo Milani &#8211; AL amyloidosis highlights</strong></p><p>Dr. Paolo Milani, University of Pavia, Italy, explains for MPE the most important AL amyloidosis updates presented at ASH 2025, as well as the role of the CAR T-cell therapy in this disease or the main challenges AL amyloidosis is facing to improve treatment outcomes.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/">ASH 2025 summary video interviews</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>MPE myeloma highlights from ASH 2025</title>
		<link>https://www.mpeurope.org/mpe-myeloma-highlights-from-ash-2025/</link>
					<comments>https://www.mpeurope.org/mpe-myeloma-highlights-from-ash-2025/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 10:34:36 +0000</pubDate>
				<category><![CDATA[AL amyloidosis]]></category>
		<category><![CDATA[Conferences]]></category>
		<category><![CDATA[MPE]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=114078</guid>

					<description><![CDATA[<p>From 6-9 December Myeloma Patients Europe (MPE) attended the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Over 20,000 researchers, doctors, nurses and patient advocates attended the meeting to share and discuss the results of the latest research from across blood cancers. ASH was a great way to close out another successful year&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/mpe-myeloma-highlights-from-ash-2025/">MPE myeloma highlights from ASH 2025</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="114078" class="elementor elementor-114078" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-aea556b elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="aea556b" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-52e5e12" data-id="52e5e12" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-bef0847 elementor-widget elementor-widget-text-editor" data-id="bef0847" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>From 6-9 December Myeloma Patients Europe (MPE) attended the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Over 20,000 researchers, doctors, nurses and patient advocates attended the meeting to share and discuss the results of the latest research from across blood cancers.</p><p>ASH was a great way to close out another <a href="https://www.mpeurope.org/mpe-year-in-review-2025/">successful year at MPE</a>, meeting with our medical, advocacy and industry partners and hearing about groundbreaking research in myeloma and AL amyloidosis. We were also privileged to present data from our own patient research <strong><em>Myeloma patients&#8217; attitudes and perceived burden of treatment administration routes and locations: insights from a pan-European survey</em>,</strong> which will soon be published in the journal <a href="https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2025.1699930/abstract" target="_blank" rel="noopener">Frontiers.</a></p><p>Below we outline the key updates in myeloma. You can see our <a href="https://youtu.be/WQzv1iA3-Io?si=q8qFqmm2MzRHmW3M" target="_blank" rel="noopener">AL amyloidosis summary interview</a> and also register for our <a href="https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/">ASH myeloma highlights webinar</a>.</p><h3><strong>Key myeloma updates</strong></h3><ul><li><h5><strong>Bispecific antibodies are transforming outcomes</strong></h5></li></ul><p>Without a doubt, the main highlight of ASH 2025 were the results of the <strong>MajesTEC-3</strong> clinical trial. <a href="https://www.youtube.com/watch?v=LEFWII_tnsc">Watch a lay friendly summary</a> with Dr. Charlotte Pawlyn from Royal Marsden Hospital and Institute of Cancer Research (ICR), London.</p><p>MajesTEC-3 is a large research study testing the combination of teclistamab (a bispecific antibody) and daratumumab (a monoclonal antibody) for patients after one – three prior lines of therapy. The teclistamab and daratumumab (Tec-Dara) combination was compared to daratumumab in combination with either pomalidomide or bortezomib with dexamethasone (DPd or DVd).</p><p>Most trials of bispecific antibodies have looked at their role in heavily pretreated myeloma patients. MajesTEC-3 is one of the first trials to show clear and unprecedented benefits of using these medicines earlier on in the myeloma pathway, in combination with other myeloma medicines.</p><p>An important note for patients to consider are the high infection rates in the Tec-Dara arm, which is consistent with other trials of bispecific antibodies. Whilst the risk of infection reduces over time and was treated in the trial with IV (intravenous – through the vein) immunoglobulins (IG) there is much discussion in the myeloma community about the role and access to IVIG to ensure that patients can receive bispecific antibody therapies safely.</p><p>We will be following the ongoing results of MajesTEC-3 with interest. We are also interested in the potential of bispecific combinations when used in newly diagnosed patients, where drugs typically get the best responses and how the community will work to seek access for these medicines.</p><ul><li><h5><strong>New CAR-Ts may be more efficient and less toxic</strong></h5></li></ul><p>Very early results were presented at ASH on <em>in vivo</em> CAR T-cell therapy (CAR-T). The currently approved CAR-Ts in Europe require  a patient’s immune cells (T-cells) to be <strong>taken out of their body</strong> and programmed to find and kill myeloma cells. <em>In vivo</em> CAR-T is where the patient’s immune cells are <strong>programmed within their body</strong>. If successful, this could mean an easier and quicker way of administering CAR-T without the need for chemotherapy whilst a patient waits for treatment.</p><p>The<strong> inMMyCAR clinical trial</strong> showed results from four myeloma patients of a CAR-T called KLN1010. KLN1010 targets BCMA which is expressed on the surface of myeloma cells. This is the first time it has been used in patients. Whilst very early, the data showed very good responses in treated patients and no serious instances of cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity Syndrome (ICANs) – two side-effects that are typical to CAR-T.</p><p><a href="https://youtu.be/gNdz4GN-fM4?si=wgzef3J19N_dFBFp">View an interview</a> with author Dr. Phoebe Joy Ho from Royal Prince Alfred Hospital and the University of Sydney, Australia.</p><p>Key discussions also centred around anitocabtagene autoleucel (anito-cel) – a BCMA CAR-T that is likely to be assessed by health authorities in the near future. Updated results of the IMMagine-1 trial again highlighted that anito-cel continues to show strong responses in relapsed myeloma patients. The side-effects reported seem to be less frequent and less severe than in other trials for similar BCMA CAR-T.</p><p>Finally, there were also a range of presentations on early and existing CAR-T therapies. Of note, the <strong>Durga-1 trial</strong> looked at optimum dosing for a “dual target CAR-T” called AZD0120. <a href="https://youtu.be/8H9oLFY8olU?si=AMEOASqoxJTBSvtq" target="_blank" rel="noopener">You can learn more about this here.</a></p><p>Most CAR T-cells are programmed to find the BCMA protein expressed on the surface of myeloma cells. Once found, it binds to and kills the myeloma cell. In the DURGA-1 trial, the CAR-T cells are programmed to find two different proteins expressed on the surface of myeloma cells &#8211; BCMA and CD19. Both BCMA and CD19 are widely expressed, making them complimentary targets for treatment. Whilst very early, the data shows promise for further exploration in myeloma. It also used FasTCAR technology which aims to manufacture CAR-T quickly, reducing delays for patients.</p><ul><li><strong>We look forward to what the coming year brings for myeloma research</strong></li></ul><p>While we can’t include every update from ASH 2025 here, if you are interested in seeing more interviews about the data, please visit our our <strong><a href="https://www.mpeurope.org/ash-2025-myeloma-and-al-amyloidosis-updates/">ASH 2025 summary video interviews.</a></strong></p><p>You can also register for our <a href="https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/">ASH myeloma highlights webinar here.</a></p><p>On a final note, with the volume of research and developments we are seeing this year in myeloma, we are looking forward to what 2026 will bring in terms of exploring new ways to optimise myeloma treatment and offer patients more effective, less burdensome medicines. We will continue to engage with our members and stakeholders to consider what these advancements mean for patients in Europe and how we can collaborate to improve access to innovative therapies.</p><p>If you have any questions or comments about ASH 2025 and the data, please, contact <a href="mailto:info@mpeurope.org">info@mpeurope.org</a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/mpe-myeloma-highlights-from-ash-2025/">MPE myeloma highlights from ASH 2025</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/mpe-myeloma-highlights-from-ash-2025/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>MPE webinar on ASH 2025 myeloma highlights</title>
		<link>https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/</link>
					<comments>https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Tue, 18 Nov 2025 11:02:30 +0000</pubDate>
				<category><![CDATA[Conferences]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=113833</guid>

					<description><![CDATA[<p>Myeloma Patients Europe (MPE) will host a webinar covering key updates on myeloma presented at the American Society of Hematology (ASH) Annual Congress, which will take place from 6–9 December 2025 in Orlando, Florida, USA. The webinar will be held on Wednesday, 17 December 2025, from 17:00 – 18:00 CET. It will be led by Prof. Dr. Hermann Einsele, Director of the Department&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/">MPE webinar on ASH 2025 myeloma highlights</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="113833" class="elementor elementor-113833" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-b73c13c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="b73c13c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-545c48e" data-id="545c48e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-4af4120 elementor-widget elementor-widget-text-editor" data-id="4af4120" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Myeloma Patients Europe (MPE) will host a webinar covering key updates on <strong>myeloma</strong> presented at the <a href="https://www.hematology.org/meetings/annual-meeting" target="_blank" rel="noopener"><strong>American Society of Hematology (ASH) Annual Congress</strong></a>, which will take place from <strong>6–9 December 2025</strong> in Orlando, Florida, USA.</p><p>The webinar will be held on <strong>Wednesday, 17 December 2025</strong>, from <strong>17:00 – 18:00 CET</strong>. It will be led by <strong>Prof. Dr. Hermann Einsele, </strong>Director of the Department of Internal Medicine II, University Hospital Würzburg, Germany. Prof. Dr. Einsele will give a 40-minute presentation followed by a 20-minute Q&amp;A session, where attendees can submit their questions.</p><p>If you are unable to attend, you can submit your questions in advance to <strong>info@mpeurope.org</strong>, and we will ensure they are addressed during the session.</p><p>A recording of the webinar will be made available after the event.</p>								</div>
				</div>
				<div class="elementor-element elementor-element-76bbe50 elementor-widget elementor-widget-spacer" data-id="76bbe50" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-f3c573d elementor-widget elementor-widget-image" data-id="f3c573d" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://mpeurope-org.zoom.us/webinar/register/WN_kEYVO6WoQ-KkPuirgSGhmg" target="_blank">
							<img decoding="async" src="https://www.mpeurope.org/wp-content/uploads/elementor/thumbs/register-now-qxq8b0vvo9xlqn3e3s46ql7j2qsi1nyzpac9ivo52y.png" title="register now" alt="register now" loading="lazy" />								</a>
															</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-8f3232a" data-id="8f3232a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-b2fa498 elementor-widget elementor-widget-image" data-id="b2fa498" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar.png" data-elementor-open-lightbox="yes" data-elementor-lightbox-title="ASH 2025 webinar" data-elementor-lightbox-description="flyer ASH 2025 webinar" data-e-action-hash="#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6MTEzODc1LCJ1cmwiOiJodHRwczpcL1wvd3d3Lm1wZXVyb3BlLm9yZ1wvd3AtY29udGVudFwvdXBsb2Fkc1wvMjAyNVwvMTFcL0FTSC0yMDI1LXdlYmluYXIucG5nIn0%3D">
							<img loading="lazy" decoding="async" width="1024" height="1024" src="https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-1024x1024.png" class="attachment-large size-large wp-image-113875" alt="ASH 2025 webinar" srcset="https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-1024x1024.png 1024w, https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-300x300.png 300w, https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-150x150.png 150w, https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-768x768.png 768w, https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar-500x500.png 500w, https://www.mpeurope.org/wp-content/uploads/2025/11/ASH-2025-webinar.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" />								</a>
															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/">MPE webinar on ASH 2025 myeloma highlights</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/mpe-webinar-on-ash-2025-myeloma-highlights/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
